Form 4: Blueprint Medicines Executive Sells Shares to Cover Tax Obligations

Percy H. Carter, Chief Scientific Officer of Blueprint Medicines, sold 3,530 shares of common stock to cover tax withholding obligations related to vesting restricted stock units.

Summary

• On March 5, 2025, Percy H. Carter, the Chief Scientific Officer of Blueprint Medicines Corp, sold 3,530 shares of common stock.
• The shares were sold at a price of $88.8 per share.
• The sale was executed to cover tax withholding obligations associated with the vesting of restricted stock units.
• Following the transaction, Carter still beneficially owns 56,865 shares of Blueprint Medicines Corp.
• The sale was not a discretionary trade but an automatic 'sell to cover' transaction to satisfy tax obligations.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing a stock sale for tax purposes, which is neither particularly positive nor negative.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, which are common occurrences in publicly traded companies. It provides transparency into the trading activities of company executives and their potential impact on the stock's price and investor sentiment.

Stakeholder Impact

• The stock sale may have a minor impact on shareholders due to the increased supply of shares, but the effect is likely to be minimal given the relatively small number of shares sold.

Key Dates